- Home
- ANTX vs MDAI Comparison
ANTX vs MDAI Comparison
Compare ANTX & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- MDAI
- Stock Information
- Founded
- ANTX 2017
- MDAI 2013
- Country
- ANTX United States
- MDAI United States
- Employees
- ANTX N/A
- MDAI N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- MDAI Medical/Dental Instruments
- Sector
- ANTX Health Care
- MDAI Health Care
- Exchange
- ANTX Nasdaq
- MDAI Nasdaq
- Market Cap
- ANTX 37.3M
- MDAI 37.8M
- IPO Year
- ANTX 2022
- MDAI N/A
- Fundamental
- Price
- ANTX $1.10
- MDAI $1.74
- Analyst Decision
- ANTX Buy
- MDAI Strong Buy
- Analyst Count
- ANTX 3
- MDAI 2
- Target Price
- ANTX $2.00
- MDAI $4.75
- AVG Volume (30 Days)
- ANTX 331.6K
- MDAI 281.3K
- Earning Date
- ANTX 05-13-2025
- MDAI 05-13-2025
- Dividend Yield
- ANTX N/A
- MDAI N/A
- EPS Growth
- ANTX N/A
- MDAI N/A
- EPS
- ANTX N/A
- MDAI N/A
- Revenue
- ANTX N/A
- MDAI $29,962,000.00
- Revenue This Year
- ANTX N/A
- MDAI N/A
- Revenue Next Year
- ANTX N/A
- MDAI $86.26
- P/E Ratio
- ANTX N/A
- MDAI N/A
- Revenue Growth
- ANTX N/A
- MDAI 55.21
- 52 Week Low
- ANTX $0.87
- MDAI $0.82
- 52 Week High
- ANTX $3.07
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- ANTX 39.89
- MDAI 70.45
- Support Level
- ANTX $1.01
- MDAI $1.57
- Resistance Level
- ANTX $1.22
- MDAI $1.73
- Average True Range (ATR)
- ANTX 0.07
- MDAI 0.10
- MACD
- ANTX -0.01
- MDAI 0.04
- Stochastic Oscillator
- ANTX 38.17
- MDAI 95.92
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.